Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target of $57.00. The company’s shares closed yesterday ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today. The company’s shares closed yesterday at $8.30. Effectively ...

Shares of NASDAQ ARVN opened at $9.03 on Tuesday. The stock has a market capitalization of $621.01 million, a PE ratio of -3.26 and a beta of 1.95. The business has a fifty day moving average ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Marketbeat reports.

Shares of Arvinas ARVN plummeted 52.7% on Tuesday after the company and partner, Pfizer PFE, announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.